The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West,
has undergone a revolution in the past few years with the development of agents that target …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Background The somatic genetic basis of chronic lymphocytic leukemia, a common and
clinically heterogeneous leukemia occurring in adults, remains poorly understood. Methods …

Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment
of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front …

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes,
involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes …

Standardized criteria for diagnosis and response assessment are needed to interpret and
compare clinical trials and for approval of new therapeutic agents by regulatory agencies …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in
the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma …

Background MicroRNA expression profiles can be used to distinguish normal B cells from
malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated …

Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …